| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一类呋喃糖环状磷酸酯阻燃剂的结构及其制备方法 | CN202010258806.6 | 2020-04-03 | CN111233947A | 2020-06-05 | 杨锦飞; 谢唯佳; 职慧珍; 黄小冬 |
| 本发明涉及一类呋喃糖环状磷酸酯阻燃剂的结构及其制备方法。该制备方法工艺简单，原料成本较低，环境污染小，且制备出的环状磷酸酯阻燃剂阻燃性能突出，易于实现工业化。 | ||||||
| 2 | 一种超临界萃取虫草脱氧核苷的生产方法 | CN01126910.3 | 2001-09-28 | CN1240706C | 2006-02-08 | 陈顺志; 高剑萍 |
| 本发明属于食用药用真菌的深加工领域，是一种超临界萃取虫草脱氧核苷的生产方法，克服了水煮、醇提、浓缩等传统工艺耗能大、时间长、繁琐的缺点，能迅速获得天然活性成份，不污染环境，而且能综合利用原料，成为食用药用真菌深加工的重要工艺，达到国际领先水平。本发明的特征是：采用乙醇作夹带剂，选择条件获得以虫草素(3’-脱氧腺苷)为主的活性成分，其纯度在50-99.9%之间，是保健食品、化妆品或药品的原料，本品有抗氧化、抗病毒、抗肿瘤，调节机体免疫力作用，也是基因工程领域的重要试剂，还可能与肾功能衰竭有关，因此本发明可以创造巨额经济效益，有广阔的开发价值。 | ||||||
| 3 | 核苷酸前药化合物 | CN202180029250.6 | 2021-04-19 | CN115605492A | 2023-01-13 | 智林 |
| 本文提供核苷酸前药化合物、其制备及其用途，诸如治疗病毒感染疾病或病症。 | ||||||
| 4 | 6-叠氮基-6-脱氧-2-N-乙酰基-己糖胺-核苷二磷酸的合成 | CN202080065627.9 | 2020-07-27 | CN114423773A | 2022-04-29 | J·胡根布姆; M·A·维基德文; J·M·M·韦卡德; F·L·范代尔夫特; S·S·范博凯尔 |
| 本发明涉及用于合成6‑叠氮基‑6‑脱氧‑2‑N‑乙酰基‑单糖‑核苷二磷酸，特别是6‑叠氮基‑6‑脱氧‑2‑N‑乙酰基‑D‑半乳糖胺‑核苷二磷酸或6‑叠氮基‑6‑脱氧‑2‑N‑乙酰基‑D‑葡糖胺‑核苷二磷酸的方法。根据本发明的合成方法的特征在于高效和高产率。本发明的另一部分是该方法的关键中间体。 | ||||||
| 5 | 一种α-氮苷类化合物的合成方法 | CN202011625629.7 | 2020-12-31 | CN112778381A | 2021-05-11 | 张琦; 郭琛; 柴永海; 吴佳荣 |
| 本发明公开了一种α‑氮苷类化合物的合成方法，该方法以三氯乙酰亚胺酯烯糖为原料，在‑20～0℃条件下，使三氯乙酰亚胺酯烯糖在三氟甲磺酸类催化剂下发生重排反应来构建α‑氮苷类化合物。本发明操作简单，催化剂廉价易得，可以以较好的收率和选择性得到α‑氮苷类化合物。并且该反应不需要添加额外的氮源来构建C‑N键，是一种具有较高原子经济性的合成方法。 | ||||||
| 6 | α－选择性糖基化反应方法 | CN200480014056.7 | 2004-05-19 | CN1795199A | 2006-06-28 | 安藤弘宗; 今村彰宏; 木曾真; 石田秀治 |
| 本发明涉及在作为单糖、或者二糖以上的低聚糖或糖链的还原末端的、6碳糖以上的糖结构体的4位和6位的羟基上，环状地形成甲硅烷基乙缩醛结构的保护基团，在此基础上，通过在该糖结构体和上述醇性羟基或硫羟基之间进行糖基化反应，以高比率得到含有α－糖苷的糖结构体糖苷的α－选择性糖基化反应方法。通过以上的构成，能够用简单且方便的方法实现糖结构体中的高度选择性α－糖基化反应。 | ||||||
| 7 | 人的白细胞间素-3及其突变蛋白质 | CN88100685 | 1988-02-16 | CN88100685A | 1988-12-14 | 大塚毅 |
| 提供了新的人白细胞间素-3蛋白质，与以前报道的人IL-3顺序相比较，它含有非保守氨基酸的取代(7位的Ser Pro)。还提供了合成构象及抗原中性的突变蛋白的方法。所公开的人IL-3蛋白可促进多种造血谱系的生长发育，因此可用于涉及血细胞再生和/或血细胞群体受抑制的病症，例如骨髓发育不全、慢性感染和利用移植骨髓的治疗。 | ||||||
| 8 | 一种α-氮苷类化合物的合成方法 | CN202011625629.7 | 2020-12-31 | CN112778381B | 2022-05-31 | 张琦; 郭琛; 柴永海; 吴佳荣 |
| 本发明公开了一种α‑氮苷类化合物的合成方法，该方法以三氯乙酰亚胺酯烯糖为原料，在‑20～0℃条件下，使三氯乙酰亚胺酯烯糖在三氟甲磺酸类催化剂下发生重排反应来构建α‑氮苷类化合物。本发明操作简单，催化剂廉价易得，可以以较好的收率和选择性得到α‑氮苷类化合物。并且该反应不需要添加额外的氮源来构建C‑N键，是一种具有较高原子经济性的合成方法。 | ||||||
| 9 | 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物 | CN201110036310.5 | 2011-02-12 | CN102286011B | 2017-10-03 | 黄才古 |
| 该发明涉及吡咯烷硼酸酯(boronate ester)DDP‑Ⅳ抑制剂，在二肽基肽酶‑Ⅳ参与的疾病如糖尿病尤其是2型糖尿病、肿瘤或其它疾病的治疗和预防中起有益作用。该发明涉及包括这些化合物的药物组合物及其在预防或治疗有二肽基肽酶‑Ⅳ参与的这些疾病中的应用。 | ||||||
| 10 | 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物 | CN201110036310.5 | 2011-02-12 | CN102286011A | 2011-12-21 | 黄才古 |
| 该发明涉及吡咯烷硼酸酯(boronate ester)DDP-Ⅳ抑制剂，在二肽基肽酶-Ⅳ参与的疾病如糖尿病尤其是2型糖尿病、肿瘤或其它疾病的治疗和预防中起有益作用。该发明涉及包括这些化合物的药物组合物及其在预防或治疗有二肽基肽酶-Ⅳ参与的这些疾病中的应用。 | ||||||
| 11 | α－选择性糖基化反应方法 | CN200480014056.7 | 2004-05-19 | CN100384862C | 2008-04-30 | 安藤弘宗; 今村彰宏; 木曾真; 石田秀治 |
| 本发明涉及在作为单糖、或者二糖以上的低聚糖或糖链的还原末端的、6碳糖以上的糖结构体的4位和6位的羟基上，环状地形成甲硅烷基乙缩醛结构的保护基团，在此基础上，通过在该糖结构体和上述醇性羟基或硫羟基之间进行糖基化反应，以高比率得到含有α-糖苷的糖结构体糖苷的α-选择性糖基化反应方法。通过以上的构成，能够用简单且方便的方法实现糖结构体中的高度选择性α-糖基化反应。 | ||||||
| 12 | Highly purified acid type sophorolipid-containing material and production method thereof | JP2014092677 | 2014-04-28 | JP2014140383A | 2014-08-07 | HIRATA YOSHIHIKO; RYU MIZUYUKI; ITO HITOSHI; ARAKI MICHIAKI |
| PROBLEM TO BE SOLVED: To provide a method for producing a highly purified acid type sophorolipid-containing material substantially not containing acetic acid.SOLUTION: The method comprises the steps of (i) and (ii-b): (i) adjusting pH of crude acid type sophorolipid (SL)-containing material to an acidic region lower than 7; and (ii-b) leaving standing still the acidified crude acid type SL-containing material obtained in the step (i) under a low temperature condition determined as in the following conditions (a) - (d) according to its pH, and then washing the generated gelled material with a cold, water-containing solvent of 15°C or lower to obtain gelatinous acid type SL-containing material. The conditions are:(a) pH4 or lower: -25°C-15°C; (b) higher than pH4 and not higher than pH5: -25°C-10°C; (c) higher than pH5 and not higher than pH6: -25°C--10°C; and (d) higher than pH6 and lower than pH7: -25°C--20°C. | ||||||
| 13 | Organic nanotube formed with boronic acid derivative having aromatic group and glycolipid, and method for producing the same | JP2010051671 | 2010-03-09 | JP2011184365A | 2011-09-22 | KAMEDA NAOHIRO; ASAKAWA MASUMI; MASUDA MITSUTOSHI; SHIMIZU TOSHIMI |
| <P>PROBLEM TO BE SOLVED: To provide an organic nanotube in which a π-electron aromatic compound having optical, electronic, and energy characteristics is introduced at high density, and to provide a simple method for producing the same. <P>SOLUTION: An ester obtained by dehydrating condensation of a glycolipid and a boronic acid derivative having an aromatic group is self-assembled in an organic solvent to form the organic nanotube. The resultant organic nanotube exhibits thermophotochromism accompanying a gel-liquid crystal phase transition phenomenon, and optical collection antenna functions in which efficient energy transfer can be made to an aromatic low molecule included in a hollow cylinder. <P>COPYRIGHT: (C)2011,JPO&INPIT | ||||||
| 14 | α- selective glycosylation process | JP2005506388 | 2004-05-19 | JP4599295B2 | 2010-12-15 | 彰宏 今村; 弘宗 安藤; 真 木曽; 秀治 石田 |
| 15 | Bile acid derivative, antilipemic drug containing methods and the it's manufacturing | JP14037593 | 1993-06-11 | JP3403218B2 | 2003-05-06 | アルフオンス・エンゼン; ヴエルナー・クラーマー; ギユンター・ヴエス; ハイナー・グロムビク |
| 16 | New polysaccharide esters and its salts | JP16176986 | 1986-07-08 | JP2569012B2 | 1997-01-08 | アウレリオ・ロメオ; フランセスコ・デラ・ヴアッレ |
| 17 | NEW MORPHOLINYL ANTHRACYCLINE DERIVATIVES | US14787667 | 2014-04-23 | US20160075730A1 | 2016-03-17 | Italo BERIA; Michele CARUSO; Vittoria LUPI |
| The present invention relates to new morpholinyl anthracycline derivatives which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them. | ||||||
| 18 | Anti-microbial peptide known as halocyntin, gene coding for said peptide, vector, transformed organism and composition containing said peptide | US10547563 | 2004-03-05 | US07439418B2 | 2008-10-21 | Guillaume Mitta; Richard Galinier; Bernard Banaigs; Eric Lasserre |
| An isolated peptide having an amino acid sequence FWGHIWNAVKRVGANALHGAVTGALS (SEQ ID No. 1), its derivatives and its fragments containing at least 7 amino acids. | ||||||
| 19 | Water-soluble sapphyrins | US417940 | 1995-04-06 | US5543514A | 1996-08-06 | Jonathan L. Sessler; Vladimir Kral |
| Sapphyrins are provided having appended functional groups that render the sapphyrin water-soluble. Such water-soluble sapphyrins are useful for photodynamic therapy, for example. | ||||||
| 20 | Total or partial esters of hyaluronic acid | US998749 | 1992-12-30 | US5336767A | 1994-08-09 | Francesco della Valle; Aurelio Romeo |
| The invention concerns the esters of hyaluronic acid in which all or only a portion of the carboxylic groups of the acid are esterified, and the salts of the partial esters with metals or with pharmacologically acceptable organic bases. The compounds possess interesting and precious bioplastic and pharmaceutical properties and may be used in innumerable fields, including cosmetics, surgery and medicine. The invention also includes pharmaceutical preparations containing, as an active ingredient, one or more hyaluronic acid esters, or a salt thereof as described above, as well as medicaments containing:1) a pharmacologically active substance or an association of pharmacologically active substances and2) a carrying vehicle containing a total or partial ester of hyaluronic acid. The invention includes also various uses of the hyaluronic esters or of the above mentioned medicaments, such as in medicine, surgery or cosmetics. The invention relates to a new procedure for the preparation of polysaccharide esters containing carboxylic groups, such as in particular the above mentioned hayluronic acid esters | ||||||
QQ群二维码
意见反馈
意见反馈